-
公开(公告)号：KR101575413B1
公开(公告)日：2015-12-21
申请号：KR1020130138570
申请日：2013-11-14
Applicant: 서울대학교산학협력단
CPC classification number: A61K35/44 , C12N5/069 , C12N2501/998 , C12N2506/1307
Abstract: 본발명은성체섬유모세포에유전자를형질도입하는단계를포함하는성체섬유모세포를형질전환(이형분화)시켜혈관내피세포를제조하는방법, 및이를통해제조된혈관내피세포를포함하는허혈성질환예방및 치료용조성물에관한것으로, 구체적으로, 본발명에서는 Foxo1, Er71, Klf2, Tal1, Lmo2 의 5개인자가성체섬유모세포의유도혈관내피세포(induced endothelial cell)로의이형분화를유도하고, 이를통해얻어진유도혈관내피세포(induced endotheliacl cell)가마우스하지허혈모델에서혈관신생을통한하지구제가가능함을확인함으로써, 본발명의허혈성질환의예방또는치료에효과적으로이용될수 있음을밝혔다.
-
公开(公告)号：KR1020150055953A
公开(公告)日：2015-05-22
申请号：KR1020130138570
申请日：2013-11-14
Applicant: 서울대학교산학협력단
CPC classification number: A61K35/44 , C12N5/069 , C12N2501/998 , C12N2506/1307
Abstract: 본발명은성체섬유모세포에유전자를형질도입하는단계를포함하는성체섬유모세포를형질전환(이형분화)시켜혈관내피세포를제조하는방법, 및이를통해제조된혈관내피세포를포함하는허혈성질환예방및 치료용조성물에관한것으로, 구체적으로, 본발명에서는 Foxo1, Er71, Klf2, Tal1, Lmo2 의 5개인자가성체섬유모세포의유도혈관내피세포(induced endothelial cell)로의이형분화를유도하고, 이를통해얻어진유도혈관내피세포(induced endotheliacl cell)가마우스하지허혈모델에서혈관신생을통한하지구제가가능함을확인함으로써, 본발명의허혈성질환의예방또는치료에효과적으로이용될수 있음을밝혔다.
Abstract translation: 本发明涉及通过使用该方法预防和治疗缺血性疾病而制备的成体成纤维细胞转化（或释放分化）和包含内皮细胞的组合物来制备内皮细胞的方法。 该方法包括将基因转导至成年成纤维细胞的步骤。 更具体地，本发明通过使用包括Foxo1，Er71，Klf2，Tal1和Lmo2在内的五个因素诱导从成体成纤维细胞诱导的诱导内皮细胞释放分化。 所获得的诱导内皮细胞可以通过缺血小鼠模型中的血管发生来治疗。 因此，本发明可以有效地应用于缺血性疾病的预防和治疗。
-
公开(公告)号：KR101496610B1
公开(公告)日：2015-02-25
申请号：KR1020140025569
申请日：2014-03-04
Applicant: 서울대학교산학협력단
CPC classification number: C12N5/0658 , C12N2501/065 , C12N2506/02 , C12N2510/00
Abstract: The present invention relates to a composition for inducing muscle cell differentiation from stem cells and a pharmaceutical composition for preventing or treating diseases related to muscle loss, which efficiently induces muscle cells from stem cells by targeting histone deacetylase 6 (HDAC6) as a new differentiation control; and can be widely used for treating and preventing diseases related to various muscle loss like muscular dystrophy, myositis and fibrosis by regenerating a loss of muscle tissues.
Abstract translation: 本发明涉及用于诱导干细胞分化肌肉的组合物和用于预防或治疗与肌肉损失有关的疾病的药物组合物，其通过靶向组蛋白脱乙酰酶6（HDAC6）作为新的分化控制来有效诱导来自干细胞的肌肉细胞 ; 可广泛用于通过再生肌肉组织的损失来治疗和预防与各种肌肉损失相关的疾病，如肌营养不良，肌炎和纤维化。
-
公开(公告)号：KR101453645B1
公开(公告)日：2014-10-23
申请号：KR1020130005902
申请日：2013-01-18
Applicant: 서울대학교산학협력단
Abstract: 본 발명은 인간 혈액 유래 혈구 세포괴(BBHS)를 이용하여 효율적으로 인슐린 분비세포로 분화하는 방법 및 이를 이용한 대사성 질환 치료제 등에 관한 것이다. 본 발명에 따라 분화된 인슐린 분비세포를 이용하여 대사성 질환 세포 치료제 개발을 실용화할 수 있을 것으로 기대되며, 본 발명에 따른 인간 혈액 유래 혈구 세포괴를 이용함으로써 줄기세포 치료제 개발과 관련한 종래의 문제점, 즉 종양발생, 면역거부, 윤리문제점, 분화방법 등을 해결할 수 있다.
-
35.发明公开식물 줄기세포 또는 식물 역분화 줄기 세포의 추출물을 이용한 맞춤형 만능줄기세포의 유도 방법 및 상기 방법에 의해 제조된 만능줄기세포 有权使用植物干细胞或丝瓜提取物衍生的细胞干细胞的方法和使用其生产的多发性干细胞
公开(公告)号：KR1020140097878A
公开(公告)日：2014-08-07
申请号：KR1020130010559
申请日：2013-01-30
Applicant: 서울대학교산학협력단
CPC classification number: C12N5/0607 , A61K8/97 , A61K8/99 , A61K2800/86 , A61Q19/00 , C12N5/0696 , C12N2500/76 , C12N2501/998
Abstract: The present invention relates to a method for deriving customized pluripotent stem cells by reprogramming differentiated adult cells using extracts of plant stem cells and callus, pluripotent stem cells produced by the method, and a cell therapy product comprising the pluripotent stem cells. According to the present invention, an ethical issue can be solved by not using eggs to produce pluripotent stem cells having the same ability as embryonic stem cells, and above all, pluripotent stem cells with secured safety can be produced by using the plant stem cell extract proven to be harmless, and also the method can be used for developing a customized immune compatible cell therapy product. Additionally, the present invention is expected to be very useful for investigating a cause of disease and studying therapy methods by deriving the pluripotent stem cells from an individual having the disease.
Abstract translation: 本发明涉及通过使用植物干细胞和愈伤组织的提取物，通过该方法产生的多能干细胞重编程分化成体细胞以及包含多能干细胞的细胞疗法产品来衍生定制多能干细胞的方法。 根据本发明，可以通过不使用卵来产生具有与胚胎干细胞相同能力的多能干细胞来解决伦理问题，并且首先，通过使用植物干细胞提取物可以产生具有安全性的多能干细胞 证明是无害的，并且该方法也可用于开发定制的免疫相容性细胞治疗产品。 此外，预期本发明对于调查疾病的病因和通过从具有该疾病的个体衍生多能干细胞来研究治疗方法是非常有用的。
-
Patent Agency Ranking
公开(公告)号：KR1020140021155A
公开(公告)日：2014-02-20
申请号：KR1020120086958
申请日：2012-08-08
Applicant: 서울대학교산학협력단
IPC: A61K35/14 , A61K35/15 , A61K35/19 , C12N5/0786
CPC classification number: A61K35/14 , A61K35/15 , A61K35/19 , C12N5/0645 , C12N2513/00
Abstract: The present invention relates to a method for stimulating lymphatic neovascularization by effectively culturing and multiplying lymph vessel adult stem cells and precursor cells, which are present in blood in a very small amount, using blood mononuclear cells; and use thereof. The present invention provides a pharmaceutical composition for stimulating lymphatic neovascularization, comprising human-blood-derived hematosphere etc. Therefore, the present invention provides a method for massively culturing and multiplying lymph vessel adult stem cells and precursor cells via the in vitro culture of self-derived blood monocyte; and a method for treating diseases having lymph vessel formation abnormality and disorder using the same. The present invention enables the massive securing of blood lymph vessel adult stem cells and precursor cells and can contribute to developing an optimal autologous-cell-derived cell therapy agent for cell therapy for lymph-vessel-related diseases.
Abstract translation: 本发明涉及一种通过使用血液单核细胞有效培养和增殖存在于血液中的淋巴管成体干细胞和前体细胞来刺激淋巴管新生血管的方法。 及其用途。 本发明提供了一种用于刺激淋巴管新生血管的药物组合物，其包含人血源性血球等。因此，本发明提供了一种通过体外培养自身的大规模培养和增殖淋巴管成体干细胞和前体细胞的方法， 衍生血液单核细胞; 以及使用该方法治疗具有淋巴管形成异常和障碍的疾病的方法。 本发明使得能够大量固定血液淋巴管成体干细胞和前体细胞，并有助于开发用于淋巴管相关疾病的细胞治疗的最佳的自体细胞来源的细胞治疗剂。
-
37.发明授权세포응집을 이용한 인간 혈액 유래 혈구 세포괴의 유도와 이를 이용한 혈중 성체줄기세포 및 전구세포의 증폭방법 및 상기의 방법에 의해 제조된 줄기세포 有权使用血液单核细胞球和茎和祖细胞扩增造血干细胞和祖细胞的方法
公开(公告)号：KR101202836B1
公开(公告)日：2012-11-20
申请号：KR1020100083482
申请日：2010-08-27
Applicant: 서울대학교산학협력단
IPC: C12N5/0789 , C12N5/0786 , C12N5/02
CPC classification number: C12N5/0647 , C12N5/0634 , C12N2502/1157 , C12N2513/00
Abstract: The present invention relates to a technique of using monocytic blood cells to effectively culture and proliferate blood adult stem cells and progenitor cells that only exist in small quantities to effectively obtain large quantities of stem cells. According to the present invention, the limitation of being able to derive only small quantities of stem cells from blood can be overcome, and the pluripotency of stem cells can easily be obtained.
-
公开(公告)号：KR1020160131259A
公开(公告)日：2016-11-16
申请号：KR1020150063203
申请日：2015-05-06
Applicant: 서울대학교산학협력단
IPC: A61K38/17 , C12N5/0789 , C07K14/705
CPC classification number: A61K35/28 , A61K38/17 , A61K2035/124 , A61P35/00 , C07K14/705 , C12N5/0081 , C12N5/0634 , C12N2502/1157 , C12N2502/1171
Abstract: 본발명은조혈모세포의세포주기를조절하는 KAI1 단백질및 이의용도에관한것으로서, 보다구체적으로는 KAI1(CD82) 폴리펩타이드또는이를코딩하는유전자를포함하는조혈모세포의세포주기조절용조성물, 또는혈액종양예방또는치료용약학적조성물에관한것이다. 본발명에따르면, KAI1(CD82)이조혈모세포의 Hierarchy 중가장최상위의조혈모세포(LT-HSC)에만발현하고, 상기 KAI1을이용하여 LT-HSC를순도높게얻을수 있는바, LT-HSC만을순도높게이식함으로써조혈모세포이식의다양한부작용을억제할 수있다. 또한, KAI1이 LT-HSC의 Quiescence(정지)에중요하게작용하며, LT-HSC의 Quiescence을유지함으로써다양한 Stress(5-FU, Irradiation)에의한세포손상에대해저항성을가지는바, 상기세포를이용하여세포뱅크를만들고세포이식을통한혈액종양세포치료제로사용될수 있을것으로기대된다.
Abstract translation: 本发明涉及一种控制造血干细胞的细胞周期的KAl1蛋白及其用途，更具体地，涉及一种包含KA1（CD82）多肽或编码其的基因的组合物，用于控制造血干细胞的细胞周期 细胞或用于预防或治疗血液肿瘤的药物组合物。 在本发明中，KA1（CD82）仅在作为造血干细胞层次上的最上层干细胞的造血干细胞（LT-HSC）中表达，可以使用KAl1获得高纯度的LT-HSC， 因此可以通过仅移植高纯度的LT-HSC来抑制造血干细胞移植的各种副作用。 此外，KAl1重要地作用于LT-HSC的静止，并且通过维持LT-HSC的静止由于各种应力（5-FU，照射）具有抗细胞损伤。 因此，预期该细胞可用于制造细胞库，并且可以通过细胞移植用作血液肿瘤细胞治疗产品。
-
公开(公告)号：KR1020160092201A
公开(公告)日：2016-08-04
申请号：KR1020150012524
申请日：2015-01-27
Applicant: 서울대학교산학협력단
IPC: A61K48/00 , A61K31/711
CPC classification number: A61K48/00 , A61K31/711
Abstract: 본발명은, AKAP6(A Kinase Anchoring Protein 6)의발현증가제를유효성분으로포함하는, 근손상질환의예방또는치료용약학적조성물에관한것이다. 본발명에의하면근재생및 근발생과정에관여하는새로운인자를규명함으로써, 이를타겟으로하는근손상질환을효율적으로치료하는방법을제공할수 있다.
Abstract translation: 本发明涉及用于预防或治疗肌肉损伤疾病的药物组合物，其包含A激酶锚定蛋白6（AKAP6）的表达启动子作为活性成分。 根据本发明，鉴定肌肉再生和肌肉生成过程中涉及的新因素，因此可以提供有效治疗针对新因素的肌肉损伤疾病的方法。
-
公开(公告)号：KR101590722B1
公开(公告)日：2016-02-03
申请号：KR1020140124556
申请日：2014-09-18
Applicant: 서울대학교산학협력단
Abstract: 본발명은인간혈액유래혈구세포괴를포함하는신경계질환치료용약학적조성물등을제공한다. 보다구체적으로, 본발명은혈액의단핵구세포을이용한효과적인 3차원배양을통해신경전구세포및 신경세포로유도하고, 궁극적으로효율적인신경세포로의분화가가능하게함으로써신경계질환을치료할수 있는새로운세포치료제개발에이용될수 있을것으로기대된다.
-
-
-
-
-
-
-
-
-
Search Results
50
records
(took 0.024 seconds)
